$24.70
1.20% yesterday
Nasdaq, Aug 25, 10:15 pm CET
ISIN
NL00150012L7
Symbol
NAMS

NewAmsterdam Pharma Company Stock price

$25.00
+2.07 9.03% 1M
+7.47 42.61% 6M
-0.70 2.72% YTD
+8.47 51.24% 1Y
+15.06 151.51% 3Y
+14.20 131.48% 5Y
+14.20 131.48% 10Y
+14.20 131.48% 20Y
Nasdaq, Closing price Fri, Aug 22 2025
+0.56 2.29%
ISIN
NL00150012L7
Symbol
NAMS
Industry

Key metrics

Basic
Market capitalization
$2.8b
Enterprise Value
$2.4b
Net debt
-
Cash
-
Shares outstanding
-
Valuation (TTM | estimate)
P/E
negative | negative
P/S
26.3 | 212.4
EV/Sales
22.7 | 183.5
EV/FCF
-
P/B
6.7
Financial Health
Equity Ratio
91.2%
Return on Equity
-16.1%
ROCE
-
ROIC
-
Debt/Equity
-
Financials (TTM | estimate)
Revenue
- | $13.3m
EBITDA
- | $-218.7m
EBIT
- | $-192.4m
Net Income
- | -
Free Cash Flow
-
Growth (TTM | estimate)
Revenue
- | -86.4%
EBITDA
- | -5,550.9%
EBIT
- | -4,782.5%
Net Income
- | -
Free Cash Flow
-
Margin (TTM | estimate)
Gross
-
EBITDA
- | -1,650.0%
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
-
FCF per Share
-
Short interest
7.6%
Employees
77
Rev per Employee
$1.3m
Show more

Is NewAmsterdam Pharma Company a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,019 stocks worldwide.

NewAmsterdam Pharma Company Stock Analysis

Unlock Scores for Free

Analyst Opinions

20 Analysts have issued a NewAmsterdam Pharma Company forecast:

18x Buy
90%
2x Hold
10%

Analyst Opinions

20 Analysts have issued a NewAmsterdam Pharma Company forecast:

Buy
90%
Hold
10%

Financial data from NewAmsterdam Pharma Company

Income Statement P&L | Balance Sheet | Cash Flow


TTM Annually
Jun '23
+/-
%
107 107
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 30 30
847% 847%
28%
- Research and Development Expense 155 155
-
145%
-147 -147
-
-137%
- Depreciation and Amortization 0.11 0.11
-
0%
EBIT (Operating Income) EBIT -147 -147
4,550% 4,550%
-137%
Net Profit -158 -158
5,603% 5,603%
-148%

In millions USD.

Don't miss a Thing! We will send you all news about NewAmsterdam Pharma Company directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

NewAmsterdam Pharma Company Stock News

Neutral
GlobeNewsWire
about 10 hours ago
NAARDEN, The Netherlands and MIAMI, Aug. 25, 2025 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not suff...

Company Profile

NewAmsterdam Pharma Co. NV is a clinical-stage biopharmaceutical company, which engages in the development of oral, non-statin medicine for patients at high risk of cardiovascular disease with residual elevation of low-density lipoprotein cholesterol. The company is headquartered in Naarden, Noord-Holland and currently employs 68 full-time employees. The company went IPO on 2022-11-23. NewAmsterdam Pharma operates as a clinical-stage company and focuses on the research and development of transformative oral therapies for major cardiometabolic diseases. The firm is investigating obicetrapib, an oral, low-dose and once-daily, cholesteryl ester transfer protein (CETP) inhibitor, as the low-density lipoprotein cholesterol (LDL-C) lowering therapy to be used as an adjunct statin therapy for high-risk cardiovascular disease (CVD) patients. The firm is also testing obicetrapib as a fixed-dose combination therapy with ezetimibe in a secondary Phase 2 trial, ROSE2, for other diseases such as Alzheimer’s disease. The firm strives to offer its products around the world.

Head office Netherlands
Employees 77
Website ir.newamsterdampharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today